The Peptide Field. Semaglutide: approval and evidence record.

Editorial review: 2026-08-30. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/semaglutide

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=semaglutide#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: Yes. Some semaglutide prescription products are FDA-approved for specific uses

Exact product limits: Ozempic, Rybelsus, and Wegovy are distinct approved products. Wegovy HD is a higher-dose Wegovy injection strength. Evidence for one product or form does not automatically apply to another.

Human outcomes: Strong. Large studies support the approved uses listed on each product label.

Body effects in people: Strong. Studies have measured how approved products act in the body and how the body processes them.

What the evidence shows: FDA-reviewed semaglutide products have approved uses and official labels. Each label says who the product is for, its warnings, side effects, and directions. Read the current label for the exact product. Do not rely on the ingredient name alone.

What remains unknown: A shared ingredient name does not make two products the same. Evidence from an approved product does not automatically apply to an unapproved, compounded, counterfeit, or research-labeled product. The name alone does not prove equal quality, safety, or results.

Safety limits: This guide does not recommend a product, say who can use it, or give dosing instructions. A licensed clinician must use the current label and a person's medical history to make treatment decisions.

Product record: Ozempic. Form: Injection. Route: Injection under the skin.
Scope: Adults with type 2 diabetes for blood-sugar control. The label also covers heart-risk reduction in adults with type 2 diabetes and established heart disease. It covers kidney-risk reduction in adults with type 2 diabetes and chronic kidney disease.
Published label: May 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf

Product record: Rybelsus. Form: Tablet. Route: Tablet by mouth.
Scope: Adults with type 2 diabetes for blood-sugar control. The label also covers heart-risk reduction in adults with type 2 diabetes who are at high risk. It is not approved for weight management.
Published label: October 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024%2Cs028s029lbl.pdf

Product record: Wegovy. Form: Injection and tablet formulations. Route: Injection under the skin or tablet by mouth.
Scope: The injection label covers weight management in defined adults and children age 12 and older. It also covers heart-risk reduction in defined adults. MASH is a liver disease. When used with a reduced-calorie diet and increased physical activity, the injection label covers MASH in adults without cirrhosis who have moderate to advanced liver scarring (F2–F3). The tablet label covers adult weight management and heart-risk reduction.
Published label: June 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf

Product record: Wegovy HD. Form: 7.2 mg injection strength. Route: Injection under the skin.
Scope: The 7.2 mg Wegovy injection strength for the adult weight-management group named in the label.
Published label: June 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf

Approval claim: “Semaglutide is FDA-approved.”
Verdict: Supported with scope. FDA approves a specific product for specific uses. The current Wegovy label lists different forms, groups of people, uses, and limits.
Evidence basis: Regulatory or product record. Scope: The exact semaglutide products, forms, people, and uses named in current FDA labels.
Claim sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024%2Cs028s029lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. OZEMPIC (semaglutide) prescribing information, revised 05/2026. 2026. Accessed 2026-08-30. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf

U.S. Food and Drug Administration. RYBELSUS (semaglutide) prescribing information, revised 10/2025. 2025. Accessed 2026-08-30. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024%2Cs028s029lbl.pdf

U.S. Food and Drug Administration. WEGOVY (semaglutide) prescribing information, revised 06/2026. 2026. Accessed 2026-08-30. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf

U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

U.S. Food and Drug Administration. Drug approvals and databases. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases

PubMed · Journal of Medicinal Chemistry. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. 2015. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/26308095/

U.S. Food and Drug Administration. FDA substance record: semaglutide identity (not an approval record). 2026. Accessed 2026-08-30. https://precision.fda.gov/ginas/app/ui/substances/6008afca-8b87-4b98-9c27-3a6878147556

World Anti-Doping Agency. 2026 Monitoring Program. 2026. Accessed 2026-08-30. https://www.wada-ama.org/sites/default/files/2025-09/2026_list_monitoring_program_en_final_clean_september_2025.pdf

Keep the limits, review date, and sources with this record. Check the current source for changes.